ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Spherix Global Insights Announces Upcoming New Special Topix™ Unpacking Payer Management Strategies Across Over 25 Therapeutic Areas

EXTON, PA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Spherix Global Insights announces the upcoming release of its latest Special Topix™ service, Payer Management Strategies, providing pharmaceutical stakeholders with critical, forward-looking intelligence into payer priorities, strategies, and evolving access dynamics across a broad range of therapeutic categories. The report will be delivered to subscribed clients at the end of the month. 
Amid rising pressure to optimize market access and anticipate the impact of policy-driven disruptions, this new service delivers critical intelligence through a unique combination of qualitative and quantitative research conducted among pharmacy and medical executives representing the leading national, Blues plans, and regional health plans and PBMs. Clients will gain insight into formulary structures, contracting pressures, biosimilar strategies, and broader policy developments, including the Inflation Reduction Act. 

Leveraging insights spanning chronic, rare, and specialty conditions—from atopic dermatitis, lupus, and multiple sclerosis to Alzheimer’s disease, oncology, and rare kidney disorders—this service provides market access and brand strategy teams with the actionable information they need to navigate today’s dynamic payer landscape. The research explores health plan–PBM relationships, formulary design trends, cost-sharing approaches, medical vs. pharmacy benefit coverage decisions, and evolving perspectives on value- and outcomes-based agreements. 

Special Topix: Payer Management Strategies will deliver real-time strategic value beyond the report itself. Clients will benefit from interactive sessions with Spherix’s therapeutic experts who offer tailored advisory support to help teams interpret the data within the context of their own brand and market dynamics. These engagements support scenario planning, highlight risks and opportunities, and provide guidance as companies prepare for access shifts anticipated through 2026. 

Built on Spherix’s proven methodology and deep therapeutic focus, Special Topix™: Payer Management Strategies reinforces the firm’s commitment to providing independent, credible insights to support strategic planning across the product lifecycle. As part of the broader Special Topix™ series, the service is designed to address emerging issues and timely topics shaping today’s specialty market environment. 

About Special Topix™ 
Special Topix™ is an independent service that includes access to a report or series of reports based on current events or topics of interest in specialty markets covered by Spherix. 

About Spherix Global Insights    

Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle.    

The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community.    

As a trusted advisor and industry thought leader, Spherix’s unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth.    

To learn more about Spherix Global Insights, visit spherixglobalinsights.com or connect through LinkedIn.     

For more details on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here: https://clientportal.spherixglobalinsights.com     

NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and analysis addressed within are based on Spherix Global Insight’s analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release.  


Pamela Lipschutz
Spherix Global Insights
4848794284
pamela.lipschutz@spherixglobalinsights.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  224.52
+3.83 (1.74%)
AAPL  274.91
+3.42 (1.26%)
AMD  213.74
+9.96 (4.89%)
BAC  51.86
+0.30 (0.58%)
GOOG  313.38
+13.73 (4.58%)
META  612.12
+17.87 (3.01%)
MSFT  475.73
+3.61 (0.76%)
NVDA  182.35
+3.47 (1.94%)
ORCL  199.71
+0.95 (0.48%)
TSLA  418.81
+27.72 (7.09%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.